FDA confirms tirzepatide scarcity remains to be over, provides compounders a grace interval

The Food and Drug Administration on Thursday confirmed {that a} scarcity of Eli Lilly’s weight problems drug tirzepatide has been resolved, a transfer that can quickly put a cease to firms making cheaper copies of the injection.

The company stated it could give these compounders a grace interval of 60 to 90 days earlier than imposing guidelines that might put a halt to their work, in an effort to keep away from disruption for sufferers.

In early October, the FDA pulled Eli Lilly’s tirzepatide — offered as Mounjaro for diabetes and Zepbound for weight problems — off its drug scarcity listing after almost two years. That ought to have prohibited compounding pharmacies from persevering with to make copies of the drug, as they’re allowed to take action solely when a therapy is on the scarcity listing. But after the commerce group the Outsourcing Facilities Association took the FDA to court docket, the company made a sudden about-face, saying it could rethink its resolution and permit compounders to proceed for the meantime.